Hedge Funds Off the Pace on ESG Integration, New BFinance Investor Poll Finds (Hedge Week)
Hedge funds are falling behind other sectors such as private equity and real estate when it comes to integrating ESG factors into their portfolios. But that tardiness may prove beneficial in avoiding other sectors’ earlier mistakes, as managers slowly adopt sustainability principles in the future, according to a new bfinance study. The survey of 256 investors – including pension funds, insurance companies, foundations, endowments, and family offices – explored their priorities and practices, as well as the challenges faced, when it comes to ESG (environmental, social and governance) and sustainable investing.
Deutsche Bank Ducks Archegos Hit, Posts Best Profits Since 2014 (Macau Business)
Germany’s largest lender Deutsche Bank reported its best quarterly profits for seven years on Wednesday, after it avoided being dragged into the collapse of US hedge fund Archegos that has inflicted deep pain on rivals. Deutsche reported better-than-expected net profits for the January to March period of 908 million euros ($1.10 billion), compared with a 43-million-euro loss a year earlier.
Venture Capital Investors Go for the Sure Bet (Preqin)
Venture capitalists in North America closed a record $71bn in deals in the first quarter as a post-COVID future moves closer to reality. North American venture capital was strong off the blocks in the first quarter of 2021, with more than $71bn (Fig. 1) in funds deployed, already half of 2020’s total. But why now? Perhaps investors are betting on a US economic recovery to pre-pandemic levels, or maybe even stronger.
Wednesday 4/28 Insider Buying Report: RAIN, BANC (Nasdaq.com)
At Rain Therapeutics, a filing with the SEC revealed that on Tuesday, Director Franklin M. Berger bought 125,000 shares of RAIN, at a cost of $16.95 each, for a total investment of $2.12M. Bargain hunters can buy RAIN at a price even lower than Berger did, with shares changing hands as low as $16.11 at last check today — that’s 5.0% below Berger’s purchase price. Rain Therapeutics is trading up about 5.8% on the day Wednesday. And also on Tuesday, PRESIDENT AND CEO Jared M. Wolff purchased $99,413 worth of Banc Of California, purchasing 5,600 shares at a cost of $17.75 each. Before this latest buy, Wolff made one other purchase in the past twelve months, buying $115,000 shares for a cost of $11.50 a piece. Banc Of California is trading up about 1.1% on the day Wednesday.
Sebi Bans 3 Entities in Infibeam Avenues Insider Trading Case (Money Control)
Regulator Sebi has barred three entities from the capital markets for one year for indulging in insider trading in the shares of Infibeam Avenues Ltd (IAL). The entities facing ban are Shah Dhiren Mahendrakumar (HUF), Amee Dhiren Shah and Affluence Fincon Service (P) Ltd, according to a final order passed by Sebi on on April 28. In addition, they have been restrained from buying, selling or otherwise dealing in securities of IAL directly or indirectly, in any manner for a period of two years.
‘Insider Trading’ in Biodiversity Offsets must be Investigated (Mirage News)
Revelations by The Guardian showing land in western Sydney was sold as biodiversity offsets for millions of dollars more than what it was bought for by individuals who worked for the environmental consultancy recommending the offsets, essentially amounts to insider trading and must be urgently investigated, says Greens MP and environment and wildlife spokesperson Cate Faehrmann.
Nucor Corp (NUE) COO David A Sumoski Sold $5.3 million of Shares (Guru Focus)
COO of Nucor Corp, David A Sumoski, sold 65,789 shares of NUE on 04/27/2021 at an average price of $80.56 a share. The total sale was $5.3 million.
The Pres-Clinical Operations & CMO of HCA Healthcare (NYSE: HCA) is Selling Shares (Analyst Ratings)
Yesterday, the Pres-Clinical Operations & CMO of HCA Healthcare (HCA), Jonathan Perlin, sold shares of HCA for $5M. Following Jonathan Perlin’s last HCA Sell transaction on February 20, 2018, the stock climbed by 102.6%. Based on HCA Healthcare’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $13.98 billion and quarterly net profit of $1.42 billion. In comparison, last year the company earned revenue of $12.86 billion and had a net profit of $581 million. The company has a one-year high of $205.58 and a one-year low of $91.21. The Company has a Price to Book ratio of 276.23.
